Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

被引:391
作者
Barbui, Tiziano
Thiele, Juergen
Passamonti, Francesco
Rumi, Elisa
Boveri, Emanuela
Ruggeri, Marco
Rodeghiero, Francesco
d'Amore, Emanuele S. G.
Randi, Maria Luigia
Bertozzi, Irene
Marino, Filippo
Vannucchi, Alessandro M.
Antonioli, Elisabetta
Carrai, Valentina
Gisslinger, Heinz
Buxhofer-Ausch, Veronika
Muellauer, Leonhard
Carobbio, Alessandra
Gianatti, Andrea
Gangat, Naseema
Hanson, Curtis A.
Tefferi, Ayalew
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Osped Riuniti Bergamo, I-24100 Bergamo, Italy
[3] Univ Pavia, Ist Ricovero & Cura Carattere Sci Policlin San Ma, I-27100 Pavia, Italy
[4] San Bortolo Hosp, Vicenza, Italy
[5] Univ Padua, Padua, Italy
[6] Univ Florence, Florence, Italy
[7] Univ Cologne, Cologne, Germany
[8] Med Univ Vienna, Vienna, Austria
关键词
CHRONIC IDIOPATHIC MYELOFIBROSIS; WORLD-HEALTH-ORGANIZATION; BONE-MARROW BIOPSY; POLYCYTHEMIA-VERA; PROGNOSTIC-FACTORS; MYELOPROLIFERATIVE NEOPLASMS; LIFE EXPECTANCY; ALLELE BURDEN; CLASSIFICATION; THROMBOSIS;
D O I
10.1200/JCO.2010.34.5298
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study examined the clinical relevance of such a distinction. Methods Representatives from seven international centers of excellence for myeloproliferative neoplasms convened to create a clinicopathologic database of patients previously diagnosed as having ET (N = 1,104). Study eligibility criteria included availability of treatment-naive BM specimens obtained within 1 year of diagnosis. All bone marrows subsequently underwent a central re-review. Results Diagnosis was confirmed as ET in 891 patients (81%) and was revised to early/prefibrotic PMF in 180 (16%); 33 patients were not evaluable. In early/prefibrotic PMF compared with ET, the 10-year survival rates (76% and 89%, respectively) and 15-year survival rates (59% and 80%, respectively), leukemic transformation rates at 10 years (5.8% and 0.7%, respectively) and 15 years (11.7% and 2.1%, respectively), and rates of progression to overt myelofibrosis at 10 years (12.3% and 0.8%, respectively) and 15 years (16.9% and 9.3%) were significantly worse. The respective death, leukemia, and overt myelofibrosis incidence rates per 100 patient-years for early/prefibrotic PMF compared with ET were 2.7% and 1.3% (relative risk [RR], 2.1; P < .001), 0.6% and 0.1% (RR, 5.2; P = .001), and 1% and 0.5% (RR, 2.0; P = .04). Multivariable analysis confirmed these findings and also identified age older than 60 years (hazard ratio [HR], 6.7), leukocyte count greater than 11 x 10(9)/L (HR, 2.01), anemia (HR, 2.95), and thrombosis history (HR, 2.81) as additional risk factors for survival. Thrombosis and JAK2V617F incidence rates were similar between the two groups. Survival in ET was similar to the sex-and age-standardized European population. Conclusion This study validates the clinical relevance of strict adherence to WHO criteria in the diagnosis of ET and provides important information on survival, disease complication rates, and prognostic factors in strictly WHO-defined ET and early/prefibrotic PMF.
引用
收藏
页码:3179 / 3184
页数:6
相关论文
共 33 条
[1]   Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients [J].
Alvarez-Larran, A. ;
Cervantes, F. ;
Bellosillo, B. ;
Giralt, M. ;
Julia, A. ;
Hernandez-Boluda, J. C. ;
Bosch, A. ;
Hernandez-Nieto, L. ;
Clapes, V. ;
Burgaleta, C. ;
Salvador, C. ;
Arellano-Rodrigo, E. ;
Colomer, D. ;
Besses, C. .
LEUKEMIA, 2007, 21 (06) :1218-1223
[2]   Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet [J].
Barbui, Tiziano ;
Barosi, Giovanni ;
Birgegard, Gunnar ;
Cervantes, Francisco ;
Finazzi, Guido ;
Griesshammer, Martin ;
Harrison, Claire ;
Hasselbalch, Hans Carl ;
Hehlmann, Rudiger ;
Hoffman, Ronald ;
Kiladjian, Jean-Jacques ;
Kroeger, Nicolaus ;
Mesa, Ruben ;
McMullin, Mary F. ;
Pardanani, Animesh ;
Passamonti, Francesco ;
Vannucchi, Alessandro M. ;
Reiter, Andreas ;
Silver, Richard T. ;
Verstovsek, Srdan ;
Tefferi, Ayalew .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) :761-770
[3]   Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis [J].
Brousseau, Maud ;
Parot-Schinkel, Elsa ;
Moles, Marie-Pierre ;
Boyer, Francoise ;
Hunault, Mathilde ;
Rousselet, Marie-Christine .
HISTOPATHOLOGY, 2010, 56 (06) :758-767
[4]   Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients [J].
Cervantes, F ;
Alvarez-Larrán, A ;
Talarn, C ;
Gómez, M ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) :786-790
[5]   Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia [J].
Chim, CS ;
Kwong, YL ;
Lie, AKW ;
Ma, SK ;
Chan, CC ;
Wong, LG ;
Kho, BCS ;
Lee, HK ;
Sim, JPY ;
Chan, CHN ;
Chan, JCW ;
Yeung, YM ;
Law, M ;
Liang, R .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) :2651-2658
[6]  
Florena AM, 2004, HAEMATOLOGICA, V89, P911
[7]   Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients [J].
Gangat, N. ;
Wolanskyj, A. P. ;
McClure, R. F. ;
Li, C-Y ;
Schwager, S. ;
Wu, W. ;
Tefferi, A. .
LEUKEMIA, 2007, 21 (02) :270-276
[8]   Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology [J].
Gianelli, Umberto ;
Vener, Claudia ;
Raviele, Paola Rafaniello ;
Moro, Alessia ;
Savi, Federica ;
Annaloro, Claudio ;
Somalvico, Francesco ;
Radaelli, Franca ;
Franco, Vito ;
Deliliers, Giorgio Lambertenghi .
LEUKEMIA & LYMPHOMA, 2006, 47 (09) :1774-1781
[9]   Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients [J].
Girodon, F. ;
Dutrillaux, F. ;
Broseus, J. ;
Mounier, M. ;
Goussot, V. ;
Bardonnaud, P. ;
Chretien, M. L. ;
Maynadie, M. .
LEUKEMIA, 2010, 24 (04) :900-903
[10]   Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele [J].
Guglielmelli, Paola ;
Barosi, Giovanni ;
Specchia, Giorgina ;
Rambaldi, Alessandro ;
Lo Coco, Francesco ;
Antonioli, Elisabetta ;
Pieri, Lisa ;
Pancrazzi, Alessandro ;
Ponziani, Vanessa ;
Delaini, Federica ;
Longo, Giovanni ;
Ammatuna, Emanuele ;
Liso, Vincenzo ;
Bosi, Alberto ;
Barbui, Tiziano ;
Vannucchi, Alessandro M. .
BLOOD, 2009, 114 (08) :1477-1483